-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $20

Benzinga·01/08/2026 12:11:50
Listen to the news
Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $23 to $20.